Corcept Therapeutics (NASDAQ:CORT) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.16) by 87.5 percent. This is a 276.47 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $164.903 million which missed the analyst consensus estimate of $192.510 million by 14.34 percent. This is a 4.89 percent increase over sales of $157.214 million the same period last year.